Exopharm Clinical Programme is not about anti-aging per se, it’s targeting age related diseases, clinically un-met needs for Dry Age-Related Macular Degeneration (AMD), Osteoarthritis (OA) & wound healing, to begin with. There are many more uses for Exosomes being researched internationally.
I think if you go to slide 23 & 24 Target Medical Conditions & Clinical Program Overview, your questions will be answered there. One of the steps is approval for use in clinical trials.
Read the Investor deck presentation in it’s entirety & I think you will then see what it’s about. Nothing to compare to ‘herbal medicine & anti-aging products’.
Of course any Human clinical trial in regenerative medicine will require Human Ethics Committee Approval & registration in relevant countries. The first human clinical trials will be conducted here in Australia.
All the information is there for those that care to read it. GLTA & wishing everyone a very happy, healthy & properous New Year for 2019.
EX1 Price at posting:
51.5¢ Sentiment: Buy Disclosure: Held
